Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643

Mortality in Mental Disorders and Global Disease Burden Implications: A Systematic Review and Meta-analysis

Walker, E. R., McGee, R. E., & Druss, B. G. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2502 · Cited by 2,976

Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine

Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258

Treatment-resistant depression and suicidality

Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

Khin, N. A., Chen, Y., Yang, Y., Yang, P., & LAUGHREN, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 211

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Capuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179338 · Cited by 37

Low-dose S-ketamine exerts antidepressant-like effects via enhanced hippocampal synaptic plasticity in postpartum depression rats

Ren, Z., Wang, M., Aldhabi, M., Zhang, R., Liu, Y., Liu, S., Tang, R., & Chen, Z. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100422 · Cited by 29

Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates

Brendle, M., Robison, R. J., & Malone, D. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.083 · Cited by 29

Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study

Glue, P., Neehoff, S., Beaglehole, B., Shadli, S. M., McNaughton, N., & Medlicott, N. J. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241227026 · Cited by 28

Intraoperative Low-Dose S-Ketamine Reduces Depressive Symptoms in Patients with Crohn’s Disease Undergoing Bowel Resection: A Randomized Controlled Trial

Zhang, Z., Yuan, Z., Zhang, W., Yi-bo, W., Cui, L.-Y., Lu, B.-X., Zhang, J., Gong, J.-F., Qing, J., Cheng, H., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031152 · Cited by 27

Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review

Kwaśny, A., Kwaśna, J., Wilkowska, A., Szarmach, J., Słupski, J., Włodarczyk, A., & Cubała, W. J. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.04.014 · Cited by 27

A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression

Joseph, B., Parsaik, A. K., Ahmed, A. T., Erwin, P. J., & Singh, B. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001317 · Cited by 26

Toward a Quantification of Anhedonia: Unified Matching Law and Signal Detection for Clinical Assessment and Drug Development

Luc, O. T., Pizzagalli, D. A., & Kangas, B. D. (2021) · Perspectives on Behavior Science · doi:10.1007/s40614-021-00288-w · Cited by 25

Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study

Jeon, H. J., Ju, P., Sulaiman, A. H., Aziz, S. A., Paik, J., Tan, W., Bai, D., & Li, C. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.70 · Cited by 25

Depression in Heart Failure with Reduced Ejection Fraction, an Undervalued Comorbidity: An Up-To-Date Review

Basile, C., Parlati, A. L. M., Paolillo, S., Marzano, F., Nardi, E., Chirico, A., Buonocore, D., Colella, A., Fontanarosa, S., Cotticelli, C., et al. (2023) · Medicina · doi:10.3390/medicina59050948 · Cited by 28

Translational Assessments of Reward Responsiveness in the Marmoset

Wooldridge, L. M., Bergman, J., Pizzagalli, D. A., & Kangas, B. D. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa090 · Cited by 27

Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti‐depressive drug on the market

Baudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 25

Evaluation of Clinical Factors Associated with Adverse Drug Events in Patients Receiving Sub-Anesthetic Ketamine Infusions

Stoker, A. D., Rosenfeld, D. M., Buras, M., Alvord, J., & Gorlin, A. W. (2019) · Journal of Pain Research · doi:10.2147/jpr.s217005 · Cited by 17

Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial

Mello, R. P., Echegaray, M. V. F., Jesus‐Nunes, A. P., Leal, G. C.-G., Magnavita, G. M., Vieira, F., Caliman‐Fontes, A. T., Telles, M., Guerreiro‐Costa, L. N. F., Souza‐Marques, B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.014 · Cited by 22

Reelin has antidepressant-like effects after repeated or singular peripheral injections

Allen, J., Romay-Tallón, R., Mitchell, M. A., Brymer, K. J., Johnston, J. N., Sánchez-Lafuente, C. L., Pinna, G., Kalynchuk, L. E., & Caruncho, H. J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109043 · Cited by 22

Transcranial direct current stimulation for bipolar depression: systematic reviews of clinical evidence and biological underpinnings

D’Urso, G., Toscano, E., Barone, A., Palermo, M., Dell’Osso, B. M., Lorenzo, G. D., Mantovani, A., Martinotti, G., Fornaro, M., Iasevoli, F., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110672 · Cited by 25

Neurocognitive impact of ketamine treatment in major depressive disorder: A review on human and animal studies

Crisanti, C., Enrico, P., Fiorentini, A., Delvecchio, G., & Brambilla, P. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.119 · Cited by 23

Antidepressant Drugs: Mechanisms of Action and Side Effects

Chang, J. P., Zamparelli, A., Nettis, M. A., & Pariante, C. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00105-5 · Cited by 22

Low-dose esketamine improves acute postoperative pain in patients undergoing thoracoscopic surgery

Zhang, Q., Wang, X., Wang, Z.-Y., & Sun, H.-L. (2024) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-023-00039-x · Cited by 21

Disrupting phosphorylation of Tyr-1070 at GluN2B selectively produces resilience to depression-like behaviors

Shi, X., Zhang, Q., Li, J., Liu, X., Zhang, Y., Huang, M., Fang, W., Xu, J., Yuan, T., Xiao, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109612 · Cited by 21

Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trail

Xu, S., Yang, J., Li, J., Zhang, M., Sun, J., Liu, Q., & Yang, J. (2024) · BMC Anesthesiology · doi:10.1186/s12871-023-02398-1 · Cited by 22

Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor

Grossert, A., Mehrjardi, N. Z., Bailey, S., Lindsay, M. A., Hescheler, J., Šarić, T., & Teusch, N. E. (2019) · Cells · doi:10.3390/cells8101139 · Cited by 20

Long-term cancer survivors treated with multiple courses of repeat radiation therapy

Christ, S. M., Ahmadsei, M., Wilke, L., Kühnis, A., Pavic, M., Tanadini‐Lang, S., & Gückenberger, M. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01934-y · Cited by 20

Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review

Chen-Li, D. C. J., Lui, L. M. W., Rosenblat, J. D., Lipsitz, O., Teopiz, K. M., Ho, R., Vinberg, M., Golts, M., Jawad, M. Y., Lee, Y. L., et al. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0082 · Cited by 20

Ketamine, benzoate, and sarcosine for treating depression

Cheng, Y., Lin, C., & Lane, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109351 · Cited by 20

Analgesic Effect of Esketamine Combined with Tramadol for Patient-Controlled Intravenous Analgesia After Cesarean Section: A Randomized Controlled Trial

Guo, Y., Ding, X., Wang, S., Wang, F., Zheng, Z., & Zou, L. (2023) · Journal of Pain Research · doi:10.2147/jpr.s427702 · Cited by 19

The Role of Colchicine in Atherosclerotic Cardiovascular Disease

Kurup, R., Galougahi, K. K., Figtree, G. A., Misra, A., & Patel, S. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.11.010 · Cited by 19

Clinical overview of NMDA-R antagonists and clinical practice

Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 19

Imbalances in Kynurenines as Potential Biomarkers in the Diagnosis and Treatment of Psychiatric Disorders

Myint, A.-M., & Halaris, A. E. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.913303 · Cited by 18

Dose‐dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study

Kawazoe, K., McGlynn, R. P., Felix, W., Sevilla, R. S., Liao, S., Kulkarni, P., & Ferris, C. F. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1035 · Cited by 18

Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex

Deyama, S., Aoki, S., Sugie, R., Fukuda, H., Shuto, S., Minami, M., & Kaneda, K. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01337-1 · Cited by 18

Determinants of health-related quality of life decline in interstitial lung disease

Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01570-2 · Cited by 18

Resolvins as potential candidates for the treatment of major depressive disorder

Deyama, S., Minami, M., & Kaneda, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.05.002 · Cited by 18

Resolution of depression: Antidepressant actions of resolvins

Deyama, S., Kaneda, K., & Minami, M. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.10.006 · Cited by 18

Molecular and Cellular Adaptations in Hippocampal Parvalbumin Neurons Mediate Behavioral Responses to Chronic Social Stress

Bhatti, D. L., Medrihan, L., Chen, M. X., Jin, J., McCabe, K. A., Wang, W., Azevedo, E. P., Ledo, J. H., & Kim, Y. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.898851 · Cited by 16

Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants

Robison, R., Brendle, M., Moore, C., Cross, H. L., Helm, L., Darling, S., Thayer, S. D., Thielking, P., & Shannon, S. M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2186285 · Cited by 17

The Effect of Opioid-Free Anesthesia with Transversus Abdominis Plane Block on Patients Undergoing Laparoscopic Sleeve Gastrectomy: Randomized Controlled Study

Zhou, X., Feng, W., Wang, X., Niu, Z., Wang, P., Li, Y., & Wang, P. (2024) · Journal of Pain Research · doi:10.2147/jpr.s471813 · Cited by 16

Polymorphisms of stress pathway genes and emergence of suicidal ideation at antidepressant treatment onset

Nobile, B., Ramoz, N., Jaussent, I., Dubois, J., Guillaume, S., Gorwood, P. A. P. M., & Courtet, P. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01003-0 · Cited by 16

Biobehavioral correlates of an fMRI index of striatal tissue iron in depressed patients

Price, R. B., Tervo‐Clemmens, B., Panny, B., Degutis, M., Griffo, A., & Woody, M. L. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01553-x · Cited by 19

Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies

Li, S. W., Kumpf, K. T., Urrutia, J., Krystal, J. H., Sanacora, G., & Wilkinson, S. T. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250276 · Cited by 16

“Novel Psychopharmacology for Depressive Disorders”

Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 15

Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial

Caliman‐Fontes, A. T., Leal, G. C.-G., Correia‐Melo, F. S., Paixão, C. S., Carvalho, M. S., Jesus‐Nunes, A. P., Vieira, F., Magnavita, G. M., Bandeira, I. D., Mello, R. P., et al. (2021) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2021-0298 · Cited by 18

New trends in pharmacological control of neuropsychiatric symptoms of dementia

Scuteri, D., Corasaniti, M. T., Tonin, P., Nicotera, P., & Bagetta, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.002 · Cited by 18

Promising new pharmacological targets for depression: The search for efficacy

Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 14

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice

Schenberg, E. E. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70097 · Cited by 14

IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain

Fernandes, M., Schelotto, M., Doldi, P. M., Milani, G., Manzano, A. A. A., Valdivia, D. P., Winter-Matos, A., Abdelrahim, Y. H., Bek, S. A. H., Benitez, B. K., et al. (2021) · F1000Research · doi:10.12688/f1000research.27809.1 · Cited by 14

Ba‐Wei‐Die‐Huang‐Wan (Hachimi‐jio‐gan) can ameliorate ketamine‐induced cystitis by modulating neuroreceptors, inflammatory mediators, and fibrogenesis in a rat model

Lee, W., Tain, Y., Chuang, Y., Tsai, C.-N., Yu, C., & Su, C. (2019) · Neurourology and Urodynamics · doi:10.1002/nau.24165 · Cited by 14

Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA‐HF Study Population: A Mathematical Modeling Analysis

Yu, H., Tang, W., Greasley, P. J., Penland, R. C., Boulton, D. W., & Hallow, K. M. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1769 · Cited by 14

Nutraceutical eicosapentaenoic acid in treatment-resistant depression: The psychoneuroimmunity and clinical implications

Chang, J. P., Iqbal, A. Z., Do, Q. L., Yaseen, M., Wu, S., Malau, I. A., Zailani, H., & Su, K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107857 · Cited by 13

S-Ketamine Improves Slow Wave Sleep and the Associated Changes in Serum Protein Among Gynecological Abdominal Surgery Patients: A Randomized Controlled Trial

Zhang, T., Song, N., Li, S., Yu, L., Xie, Y., Yue, Z., Zhang, R., Wang, L., & Tan, H. (2023) · Nature and Science of Sleep · doi:10.2147/nss.s430453 · Cited by 15

Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression

Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 15

Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study

Liu, X., Wei, Z., Li, L., Li, J., Deng, Y., Liu, Y., Li, H., Peng, D., Wan, X., & Wu, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.002 · Cited by 15

Trends in poisonings involving ketamine in the United States, 2019–2023

Palamar, J. J., Jewell, J. S., Shahawy, O. E., & Black, J. C. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112549 · Cited by 13

U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression

Katz, E. G., McNulty, P., Levitan, B. S., Treichler, P., Martynowicz, J., & Jamieson, C. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00340-6 · Cited by 13

Is there a risk of esketamine misuse in clinical practice?

Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 16

Functional and Molecular Changes in the Prefrontal Cortex of the Chronic Mild Stress Rat Model of Depression and Modulation by Acute Ketamine

Mingardi, J., Ndoj, E., Bonifacino, T., Misztak, P., Bertoli, M., Via, L. L., Torazza, C., Russo, I., Milanese, M., Bonanno, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310814 · Cited by 13

Biomarker innovations in precision psychiatry diagnostics and treatment strategies

Kas, M. J., Kim, Q., Sand, M. S., Kozak, R., Tunbridge, E. M., Oquendo, M. A., Tamminga, C. A., Koutsouleris, N., Knudsen, G. M., Penninx, B. W. J. H., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112762 · Cited by 16

Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis

Rhee, T. G., Shim, S. R., Popp, J. H., Trikalinos, T. A., Rosenheck, R. A., Kellner, C. H., Seiner, S. J., Espinoza, R. T., Forester, B. P., & McIntyre, R. S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02366-8 · Cited by 12

Comparing the adverse effects of ketamine and esketamine between genders using FAERS data

Yang, X., & Chen, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329436 · Cited by 16

The Challenge of Antidepressant Therapeutics in Alzheimer’s Disease

Lozupone, M., Montagna, M. L., D’Urso, F., Piccininni, C., Rinaldi, A., Beghi, M., Cornaggia, C., Sardone, R., Solfrizzi, V., Daniele, A., et al. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-42667-5_10 · Cited by 10

REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats

Bifari, F., Pappagallo, M., Bleavins, M. R., Traversa, S., Folli, F. B., & Manfredi, P. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863959 · Cited by 11

Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine

Shoib, S., Kotra, M., Javed, S., Nguyen, V.-S., & Malathesh, B. C. (2022) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0099 · Cited by 11

Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies

Chen, M., Cheng, C., Li, C., Tsai, S., Lin, W., Bai, Y., & Su, T. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114749 · Cited by 11

Esketamine Anesthetizes Mice With a Similar Potency to Racemic Ketamine

Ma, X., Peng, J., Chen, Y., Wang, Z., Zhou, Q., Yan, J., & Jiang, H. (2023) · Dose-Response · doi:10.1177/15593258231157563 · Cited by 11

Agmatine potentiates antidepressant and synaptic actions of ketamine: Effects on dendritic arbors and spines architecture and Akt/S6 kinase signaling

Freitas, A. E., Heinrich, I. A., Moura, T. D. M., Fraga, D. B., Costa, A. P., Azevedo, D., Brocardo, P. S., Kaster, M. P., Leal, R. B., & Rodrigues, A. L. S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113398 · Cited by 11

Disturbances in branched-chain amino acid profile and poor daily functioning in mildly depressed chronic obstructive pulmonary disease patients

Pinson, M. R., Deutz, N. E. P., Harrykissoon, R., Zachria, A. J., & ENGELEN, M. P. K. J. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01719-9 · Cited by 11

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation

Tian, J., Xie, Y., Ye, S., Hu, Y., Feng, J., Li, Y., Lou, Z., Ruan, L., & Wang, Z. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151965 · Cited by 10

Efficacy of esketamine nasal spray for treatment-resistant depression: a meta-analysis of randomized controlled studies

Ouyang, Y., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000041495 · Cited by 10

Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression

Guhathakurta, D., Petrušková, A., Akdaş, E. Y., Perelló‐Amorós, B., Frischknecht, R., Anni, D., Weiss, E., Walter, M., & Fejtová, A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02744-y · Cited by 10

Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response

Derosa, S., Misztak, P., Mingardi, J., Mazzini, G., Müller, H. K., & Musazzi, L. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110871 · Cited by 10

Does depression with current suicidal ideation lead to treatment-resistant depression? Two large naturalistic cohorts of outpatients with depression and current suicidal ideation

Nobile, B., Gourguechon-Buot, E., Malestroit, M., Olié, É., Haffen, É., Gorwood, P. A. P. M., & Courtet, P. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116249 · Cited by 10

Dexmedetomidine in the Treatment of Depression: An Up-to-date Narrative Review

Al-Mahrouqi, T., Al‐Alawi, M., & Freire, R. C. R. (2023) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/17450179-v19-230823-2023-4 · Cited by 9

Do classic psychedelics increase the risk of seizures? A scoping review

Soto-Angona, Ó., Fortea, A., Fortea, L., Martínez-Ramírez, M., Santamarina, E., Gil-López, F., Knudsen, G. M., & Oña, G. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.05.002 · Cited by 9

Effects of the subanesthetic dose of esketamine on postoperative sleep quality in patients undergoing modified radical mastectomy: a randomized, double-blind controlled trial

Chen, Y., He, J., Huang, R., Pan, Z., Zhong, M., & Zhang, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1552934 · Cited by 9

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice

Gobbi, G., Inserra, A., Greenway, K. T., Lifshitz, M., & Kirmayer, L. J. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119388 · Cited by 10

Antidepressant-like effect of acute dose of Naringin involves suppression of NR1 and activation of protein kinase A/cyclic adenosine monophosphate response element-binding protein/brain-derived neurotrophic factor signaling in hippocampus

Wang, G., Yang, H., Zuo, W., & Mei, X. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000713 · Cited by 9

Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence

Caliman‐Fontes, A. T., Vieira, F., Leal, G. C.-G., Carneiro, B. A., Quarantini-Alvim, Y., Andrade, T. V., Mello, R. P., Gadelha, A., Lacerda, A. L. T., & Quarantini, L. C. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.07.055 · Cited by 9

Fast-acting antidepressant-like effects of ketamine in aged male rats

Hernández‐Hernández, E., Ledesma‐Corvi, S., Jornet-Plaza, J., & García-Fuster, M. J. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00636-y · Cited by 7

Is esketamine-based opioid-free anesthesia more superior for postoperative analgesia in obstructive sleep apnea patients undergoing bariatric surgery? A study protocol

Guo, Y., Chen, L., Gao, Z., Zhang, M., Liu, M., Gao, X., Liu, Y., Zhang, X., Guo, N., Sun, Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1039042 · Cited by 9

Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways

Łysik, A., Logoń, K., Szczygieł, A., Wołoszczak, J., Wrześniewska, M., & Leszek, J. (2025) · GeroScience · doi:10.1007/s11357-025-01615-8 · Cited by 11

Environmental determinants of ketamine’s prohedonic and antianhedonic efficacy: Persistence of enhanced reward responsiveness is modulated by chronic stress

Jenkins, A. R., Radl, D. B., Kornecook, T. J., Pizzagalli, D. A., Bergman, J., Buhl, D. L., O’Donnell, P., & Kangas, B. D. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103572 · Cited by 8

Effect of Intraoperative Intravenous Infusion of Esketamine Combined with Dexmedetomidine on Postoperative Sleep Disturbance in Patients Undergoing Radical Mastectomy

Geng, X., Pu, Y., Hu, Z., Zhang, H., Wang, M., Fang, C., Lv, G., Li, W., Zhang, X., Fan, X., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s510222 · Cited by 8

Clinical Benefits and Challenges of Esketamine in Elderly Patients During the Perioperative Period

Zhang, S., Bai, C., Xu, M., Li, Y., Han, Y., Jin, Y., & Zhao, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s536813 · Cited by 9

Potent and reversible open-channel blocker of NMDA receptor derived from dizocilpine with enhanced membrane-to-channel inhibition

Misiachna, A., Konecny, J., Kolcheva, M., Ladislav, M., Prchal, L., Netolický, J., Kortus, Š., Zahumenska, P., Langore, E., Novak, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117201 · Cited by 8

Use of Patient Preferences Data Regarding Multiple Risks to Inform Regulatory Decisions

Montano-Campos, J. F., González, J. M., Rickert, T., Fairchild, A. O., Levitan, B. S., & Reed, S. D. (2023) · MDM Policy & Practice · doi:10.1177/23814683221148715 · Cited by 8

Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui

Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000268 · Cited by 7

Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance

Black, J. C., Monte, A. A., Dasgupta, N., Jewell, J. S., Rockhill, K. M., Olson, R. A., & Dart, R. C. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00233-1 · Cited by 7

Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing

Hu, X., Wu, J., He, Q., Xiong, Z., & Li, N. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101045 · Cited by 8

Changes in dynamic and static functional connectivity in amygdala subregions in major depressive disorder treated with esketamine in and sertraline: A pilot study

Liu, X., Li, L., Li, H., Deng, Y., Liu, Y., Peng, D., Wu, G., & Zhou, X. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120156 · Cited by 7

Anhedonia and depression severity measures during ketamine administration in treatment-resistant depression

Kwaśny, A., Cubała, W. J., & Włodarczyk, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1334293 · Cited by 7

Understanding and treating postpartum depression: a narrative review

Cardaci, V., Carminati, M., Tondello, M., Pecorino, B., Serretti, A., & Zanardi, R. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000560 · Cited by 7

CircKat6b Mediates the Antidepressant Effect of Esketamine by Regulating Astrocyte Function

Hu, N., Zheng, Y., Liu, X., Jia, J., Feng, J., Zhang, C., Liu, L., & Wang, X. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04420-0 · Cited by 7

Arketamine: a scoping review of its use in humans

Leal, G. C.-G., Lima-Araújo, I., Roiter, D. G., Caliman‐Fontes, A. T., Mello, R. P., Kapczinski, F. P., Lacerda, A. L. T., & Quarantini, L. C. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01945-2 · Cited by 7

Glutamatergic Agents for the Treatment of Cocaine Use Disorder

Hadizadeh, H., Flores, J. M., Mayerson, T. F., Worhunsky, P. D., Potenza, M. N., & Angarita, G. A. (2022) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-022-00252-1 · Cited by 7

Anesthesia for patients with psychiatric illnesses: a narrative review with emphasis on preoperative assessment and postoperative recovery and pain

Stamenković, D., Selvaraj, S., Venkatraman, S., Arshad, A., Rančić, N., Dragojevic-Simic, V. M., Miljković, M. N., & Cattano, D. (2020) · Minerva Anestesiologica · doi:10.23736/s0375-9393.20.14259-7 · Cited by 8

Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review

Brendle, M., Ragnhildstveit, A., Slayton, M. A., Smart, L., Cunningham, S. R., Zimmerman, M. H., Seli, P., Gaffrey, M. S., Averill, L. A., & Robison, R. J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00234 · Cited by 8

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study

Liu, X., Liu, Y., Tu, J., Li, L., Long, T., Li, J., Deng, Y., Li, H., Peng, D., & Wu, G. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.016 · Cited by 6

An Intraoperative Sub-Anesthetic Dose of Esketamine on Postoperative Depressive Symptoms in Perimenopausal Women with Breast Cancer Undergoing Modified Radical Mastectomy: Protocol for a Randomized, Triple-Blinded, Controlled Trial

Liu, L., Hu, J.-H., Pan, J., Liu, H., Ji, F., & Peng, K. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s421265 · Cited by 6

A synopsis of multitarget therapeutic effects of anesthetics on depression

Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 6

Ketamine for Adults With Substance Use Disorders

Tran, K. T., & MacDougall, D. (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.845 · Cited by 6

Esketamine nasal spray offers rapid improvement in treatment‐resistant depression

(2019) · The Brown University Psychopharmacology Update · doi:10.1002/pu.30468

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Turner, E. H. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30394-3 · Cited by 156

Esketamine: the first glutamatergic drug for the management of treatment- resistant depression

Musazzi, L. (2020) · doi:10.36118/pharmadvances.03.2020.02 · Cited by 1

Esketamine Approved for Refractory Depression

D’Arrigo, T. (2019) · Psychiatric News · doi:10.1176/appi.pn.2019.4a28

Esketamine for treatment resistant depression

Jauhar, S., & Morrison, P. (2019) · BMJ · doi:10.1136/bmj.l5572 · Cited by 40